Physician profile
Eric R Shives
NPI 1982751533
$13,064.44
in general payments reported to CMS, 2019-2025
51 companies · $2,086 in 2025
The $2,086 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,553 · 2020: $1,755 · 2021: $1,969 · 2022: $1,371 · 2023: $2,187 · 2024: $2,144 · 2025: $2,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,417.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,406.03 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,357.74 | 2019-2025 | |
| Abbvie INC. | $1,312.41 | 2020-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $1,306.22 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $897.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $780.13 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $742.96 | 2019-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $428.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $419.19 | 2019-2024 | Glassia, Trintellix |
| Amgen INC. | $397.61 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $389.38 | 2023-2025 | |
| Astellas Pharma US INC | $378.55 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $363.18 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.11 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $251.90 | 2019-2024 | Xarelto |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Shives listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.